Log In
Print
BCIQ
Print
Print this Print this
 

vaniprevir (MK-7009)

  Manage Alerts
Collapse Summary General Information
Company Merck & Co. Inc.
DescriptionHCV NS3/4A protease complex inhibitor
Molecular Target HCV NS3/4A protease complex
Mechanism of ActionViral protease inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentRegistration
Standard IndicationHepatitis C virus (HCV)
Indication DetailsTreat HCV infection
Regulatory Designation

Japan - Standard Review (Treat HCV infection)

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today